Stay Informed

WNDM Medical Inc.

With our number one goal of improving patient outcomes, WNDM Medical Inc., develops, markets and distributes biotechnology products to physicians, hospitals and clinics. We have a strong history of developing long-term, strategic partnerships with a focus on products that fuse nature with science. With a steady focus on innovation and growth, we hold licenses and patents to technologies and processes that ultimately make a positive impact on clinical outcomes for patients.

Our primary products are in the $11 billion U.S. consumable medical device market and in the $1.5 billion biomaterials market. We project rapid revenue growth based on increasing sales from our FDA-cleared CellerateRX® Surgical Activated Collagen® Adjuvant, as well as anticipated revenues from our FDA-cleared HemaQuell® Resorbable Bone Hemostat.


Innovation isn't born. It's bred. That’s why our approach to product development merges science and technology with the goal of creating innovative, safe and cost-effective products for the ever-changing surgery landscape.

Valid in most surgical specialties, our products are cost-effective across the continuum of care. They are supported by our growing internal sales management team and a network of seasoned health care distributors.




logo HemaQuell3

When normal bone healing and fusion are critical, HemaQuell Hemostat provides rapid hemostasis by filling in cut or damaged bone surfaces with a simple, ready-to-use application. And because it is completely resorbed in just 2-7 days, it allows bone to heal normally without interference. Learn more about patient benefits.


logo CellerateRX Surgical3

CellerateRX® Surgical is changing collagen’s role in the operating room across specialties where comorbidities and postoperative incisional healing risks are a concern. Find out how CellerateRX® Surgical provides a favorable environment for healing and can help high-risk patients.



WNDM Medical Inc., is an emerging commercial stage company with its primary products in the $11 billion U.S. consumable medical device market and in the $1.5 billion biomaterials market. Our primary focus is the distribution of our unique, patented CellerateRX® Surgical Activated Collagen® Adjuvant, which is FDA-cleared and indicated for all surgical and traumatic wounds, except third degree burns. We have also received FDA-clearance for HemaQuell® Resorbable Bone Hemostat.

WNDM Medical Inc.’s Code of Ethics

Contact Us

Contact Form


WNDM Medical Inc.

1200 Summit Avenue
Suite 414
Fort Worth, TX

Phone: 817-529-2300